While many vendors are claiming agile IRT capabilities, it is important to dig deeply and examine these claims – as well as a company’s proven ability to provide predictable, consistent delivery of project timelines and quality.
How a CRO is leveraging the eClinical versatility necessary to succeed in a broad array of studies.
A summary of the clinical relevance of RNA-Seq as well as when and how to use gene expression profiling for biomarker discovery for immunotherapy trials.
In the world of clinical trials and GxP activities, without documented evidence of an event, you cannot confirm what really happened. Learn how one large pharmaceutical customer, at risk of non-compliance to GDP due to a downturn in temperature data, improved their monitor compliance upload rate.
Late Phase Research in the Life Sciences segment is undergoing a rapid transformation due to the digitalisation of healthcare and the greater availability of, and access to, Real World Data (RWD). This transformation is arriving not a moment too soon, given the changes anticipated from the Twenty-first Century Cures Act, EMA’s Adaptive Pathways approach, and the increased demand for Real World Evidence (RWE) generated from these RWD. In addition to supporting regulatory decisions, RWE is playing an ever expanding role in developing the product value propositions that are driving reimbursement decisions globally.
Immune repertoire profiling provides better outcomes for immuno-oncology development programs .
Learn six strategies for success when developing your companion diagnostic.
Current MRD detection landscape, key considerations for each approach, and current advancements that will contribute to further improvements in MRD detection.
Sponsors who partner with a global central laboratory should expect optimized outcomes resulting from a depth of immuno-oncology and technological expertise and harmonized processes.
|
|
|
|
|
|
|
|
|